Annual Information Update

RNS Number : 1377S

Hikma Pharmaceuticals Plc

12 May 2009

 



Annual Information Update

LONDON, 12 May 2009. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ('Hikma' or 'the Company')(LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/).The Stock Exchange announcements made during the defined period are:

Date of announcement	Headline of announcement
11 May 09	Director/PDMR Shareholding
11 May 09	Total Voting Rights
16 Apr 09	Director/PDMR Shareholding
09 Apr 09	Annual Financial Report
19 Mar 09	Director/PDMR Shareholding
18 Mar 09	Director/PDMR Shareholding
17 Mar 09	Final Results
26 Jan 09	Holding(s) in Company
15 Jan 09	Director/PDMR Shareholding
14 Jan 09	Trading Statement
02 Jan 09	Total Voting Rights
03 Dec 08	Total Voting Rights
25 Nov 08	Statement re Injectables Presentation
05 Nov 08	Interim Management Statement
03 Nov 08	Total Voting Rights
22 Oct 08	Blocklisting Interim Review
17 Oct 08	Director/PDMR Shareholding
13 Oct 08	Director/PDMR Shareholding
03 Oct 08	Total Voting Rights
15 Sept 08	Director/PDMR Shareholding
02 Sept 08	Total Voting Rights
28 Aug 08	Interim Results
06 Aug 08	Total Voting Rights
21 Jul 08	Trading Statement
02 Jul 08	Total Voting Rights
25 Jun 08	Director/PDMR Shareholding
25 Jun 08	Holding(s) in Company
15 May 08	Results of Annual General Meeting
15 May 08	AGM and IMS
15 May 08	TR-1 Notifications of Major Shareholding
12 May 08	Annual Information Update

All of the above announcements were also made by the Company via the NasdaqDubai stock exchange CANDI system. These announcements may be viewed and downloaded from the NasdaqDubai website (www.candi.nasdaq.com).  

Documents filed with the Financial Services Authority

The company has filed the following documents with the Financial Services Authority ('FSA') over the previous 12 months. These documents are available to be viewed via the UKLA's Document Viewing Facility at the Financial Services Authority, 25 the North Colonnade, London, E14 5HS or at the Company's registered office.

Documents Filed with the Document Viewing Facility

Date	Document
9 April 2009	Annual Report and Accounts 2008
9 April 2009	Notice of Annual General Meeting and Proxy Voting Card
15 May 2008	Articles of Association, Ordinary and Special Resolutions passed at the 2008 AGM

Documents filed with Companies House

The Company submitted filings to Companies House in relation to the Company's annual return, financial report & accounts, allotments of shares, Articles of Association, and ordinary and special resolutions passed at the company's 2008 Annual General Meeting.  Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk. 

Copies of all documents can be obtained from the Company at the registered office, 13 Hanover Square, London, W1S 1HW. 

Henry Knowles
Company Secretary
12 May 2009

- ENDS -

Enquiries:

Hikma Pharmaceuticals plc Henry Knowles, Company Secretary Susan Ringdal, Investor Relations Director	[phone]
Brunswick Group LLP Jon Coles / Justine McIlroy / Alex Tweed	[phone]

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.  Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2008, the Group achieved revenues of $580.7 million (2007 $449 million) and profit attributable to shareholders was $57.1 million (2007 $63 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

AIUQLLFFKEBXBBE